Study Also Shows 36% Reduction in Risk of Heart Attack VESALIUS-CV is a Phase 3, double-blind, randomized, placebo-controlled global clinical trial designed to evaluate the impact of LDL-C lowering ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Amgen’s cholesterol drug Repatha proved effective at lowering the risk of heart attacks, strokes and death in patients with heart disease in a recent clinical trial, reports Reuters. When reporting ...
Repatha was first approved in 2015 and has since been used by more than 6.7 million patients globally. 3,4 Earlier this year, the U.S. Food and Drug Administration broadened the approved use of ...
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback